Hemispheric

Name: Hemispheric
Brand: Hemisphere

Hemispheric is a NeuroAI platform that decodes non-invasive brain activity (EEG plus behavioral data) into quantitative neural biomarkers and task outputs via an API-centered model offering (Descartes 1.0).

Est 2019

LinkedIn 3K|Website|FTEs 112|HQ Tel Aviv, Israel

Published Oct 12, 2026

01Common complaints

- Scenarios where alternatives are better - When an off-the-shelf EEG system with established purchasing and broad community usage is required: - Consider Emotiv or other established EEG vendors. - When transparent public security and compliance documentation is required prior to procurement: - Hemispheric does not publicly document SOC 2/ISO/enterprise controls in accessible sources; vendors with published compliance artifacts may be easier to approve. - When a consumer-ready form factor is needed immediately: - Consider Neurable or other consumer neuro-wearable products. - When clinically validated and regulated solutions are required immediately: - Consider vendors with explicit medical device positioning and available evidence packages; Hemispheric’s regulatory status was not clear from public sources. - When an organization cannot support high-quality EEG acquisition and artifact management: - Non-invasive EEG performance depends on acquisition quality; if operational capability for controlled data collection is lacking, results may be unreliable. - Red flags in the buying process - A gated "apply for access" process without published documentation of SLAs, data ownership, and validation standards can be a risk for time-sensitive programs. - Current limitations acknowledged by the vendor - Accessible marketing content emphasizes capabilities; explicit vendor-acknowledged limitations were not found. - Features on the roadmap - Not publicly documented. - Scale limitations - Not publicly documented; foundation-model approaches can be expensive to run, so cost and latency may be constraints. - Security or compliance gaps - Public-facing security and compliance documentation appears limited or absent. - Technical debt or architectural limitations mentioned in reviews - Not available. - API limitations or integration constraints - API access appears gated; public API documentation for Descartes was not located in accessible searches.

Deal disqualifiers (what makes a POOR fit)

Need for immediate, turnkey clinical diagnostic claims without a validation program.
Procurement processes that mandate published compliance reports and a mature security posture before vendor engagement.
Low tolerance for opaque pricing and gated access.

Why some customers left for competitors (churn reasons)

Not available from public review sources.

02Why they buy

- Competitive advantages validated by customer feedback (not just vendor claims) - Insufficient independent customer feedback was found to validate unique selling points. - Unique features and capabilities competitors lack (per vendor claims) - Vendor-stated characteristics for Descartes 1.0 include: - 6 billion parameter model architecture (vendor-stated). - Training on a large amount of EEG and behavioral data (vendor-stated: 250,000 hours; 100,000+ participants). - A claimed foundation-model approach and scaling behavior applied to neuroscience tasks. - Differentiation from competitors based on reviews - Not possible due to lack of independent reviews. - Areas where competitors clearly have advantages - Emotiv: mature commercial ecosystem and accessibility. - Kernel: more transparent pricing and developer materials. - Neuroelectrics: clinical device orientation.

Why customers chose this product over alternatives

No independent reviews found; inferred reasons based on vendor positioning include claims of large dataset scale and a foundation-model approach that could reduce per-task model training requirements.

03Field reports

- Public case studies - No formal case studies were found on Hemispheric's public website or accessible vendor materials. - Vendor/press-reported results (not independently validated) - Press reports indicate the company tested subsets of people (including some with mental health conditions) and reported the ability to infer aspects of brain health. These claims are based on company statements and press reporting without full methodology disclosure, endpoints, peer-reviewed outcomes, or clear regulatory status. - Critical evaluation - For precision-diagnostics claims, prospective buyers should request the following evidence from the vendor: - Clinical validation design (prospective vs retrospective, multi-site, sample sizes). - Definitions of gold-standard comparators. - Demographic and device generalization analyses. - Artifact handling methodology and robustness testing in real-world conditions. - Evidence packages aligned to the intended regulatory pathway (FDA/CE) if clinical use is intended.

Important context: availability of review data

Hemispheric is not widely listed on mainstream B2B review platforms (G2, TrustRadius, Gartner Peer Insights) in accessible search results.
Searches referencing the company on discussion forums returned limited product-usage commentary.

Gartner Peer Insights

Attempts to locate Hemispheric-specific reviews were unsuccessful; accessible results returned general Gartner pages rather than a Hemispheric vendor listing.

G2

No Hemispheric product listing with reviews was found in accessible results.

TrustRadius

No Hemispheric product listing with reviews was found in accessible results.

Reddit / community

Community discussion about the company is sparse. A Reddit post linking to a press article was identified, but comments do not constitute product-usage reviews and often reflect general skepticism about AI.

What vendor-provided "testimonials" or claims exist (vendor/press narrative, not peer reviews)

- Vendor statements include: - Descartes 1.0: described by the vendor as built with a very large parameter count, trained on extensive non-invasive EEG data spanning many hours and sourced from a large number of participants; the vendor asserts the model generalizes to new people. - Press framing: reporting has described the product direction as aiming to make certain brain diagnostics less costly and to use large-scale non-invasive data to infer brain health.

Common criticisms and complaints (from available sources)

- No substantial public end-user complaint patterns were identified in mainstream review or community sources. - Category-level risks that remain relevant until independently validated: - Non-invasive EEG data can be noisy and may struggle with generalization across individuals and settings. - Risk that accuracy claims are overstated in the absence of transparent clinical validation. - Potential privacy and consent concerns for large-scale brain datasets.

Deal-breakers and reasons customers didn’t purchase

Not available via public reviews; likely deal-breakers for enterprise buyers include lack of published security/compliance posture, unclear pricing, and unclear regulatory readiness.

04Best fit

Company sizes

Likely best fit: mid-market to enterprise research organizations with budgets for clinical validation and data collection; well-funded startups and large pharma R&D groups working on CNS pipelines.

Industries and verticals

Healthcare and digital health (brain health, psychiatry, neurology).
Pharma/biotech/CROs (CNS trials, biomarker discovery).
Academic and institutional neuroscience.
Government/defense research.

Roles and personas

Decision makers
- Head of Neuroscience / Translational Medicine
- VP Clinical Development (CNS)
- Chief Medical Officer / Clinical Science leads
- Head of Data/AI in R&D
End users
- Neuroscientists
- Clinical researchers
- Data scientists / ML engineers
- EEG technicians (or vendor-operated lab staff)

Pain points and challenges the product addresses

Need for objective, quantitative measures of brain state beyond symptom questionnaires.
Need for scalable biomarkers for CNS trials.
Desire to avoid invasive implants and expensive imaging when suitable non-invasive alternatives exist.

Qualification criteria (what makes a GREAT fit)

Capability to run controlled EEG data collection and maintain protocol quality.
Willingness to engage in co-development and validation rather than a purely "plug-and-play" procurement.
Clear intended use (research tool vs clinical decision support) and governance.

05The pitch

What the product does (core value proposition in objective terms)

- Hemispheric describes itself as a NeuroAI company building models aimed at decoding non-invasive brain activity (notably EEG plus behavioral data) into measurable outputs intended to inform downstream decisions. - The flagship model/product branding on the site is **"Descartes 1.0"**, described by the vendor as a large NeuroAI model. Hemispheric states Descartes is trained on a proprietary multimodal EEG + behavioral dataset and that it generalizes to new people and new decoding tasks. - In practical terms, the implied product direction is a platform/API that outputs quantitative metrics and insights derived from non-invasive brain recordings for use in brain health, CNS R&D, and potentially other sectors.

Target market and market positioning

- Hemispheric appears positioned as a platform-layer provider for organizations seeking quantitative neural biomarkers derived from non-invasive measurements. - Likely early customers and partners (inferred from messaging): - Pharma / biotech / CROs conducting CNS drug discovery and trials (objective measurement of treatment response). - Healthcare and brain-health providers seeking diagnostic decision support. - Research institutions. - Government/defense research programs (the company and third-party profiles reference defense settings).

Get a comprehensive analysis of Hemispheric including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →